Chalepin and Chalepensin: Occurrence, Biosynthesis and Therapeutic Potential by Nahar, L et al.
 
Nahar, L, Al-Majmaie, S, Al-Groshi, A, Rasul, A and Sarker, SD




LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Nahar, L, Al-Majmaie, S, Al-Groshi, A, Rasul, A and Sarker, SD (2021) 
Chalepin and Chalepensin: Occurrence, Biosynthesis and Therapeutic 




Chalepin and Chalepensin: Occurrence, Biosynthesis and
Therapeutic Potential
Lutfun Nahar 1,* , Shaymaa Al-Majmaie 2, Afaf Al-Groshi 2 , Azhar Rasul 3 and Satyajit D. Sarker 2,*


Citation: Nahar, L.; Al-Majmaie, S.;
Al-Groshi, A.; Rasul, A.; Sarker, S.D.
Chalepin and Chalepensin:
Occurrence, Biosynthesis and
Therapeutic Potential. Molecules 2021,
26, 1609. https://doi.org/10.3390/
molecules26061609
Academic Editor: Maria João Matos
Received: 24 February 2021
Accepted: 12 March 2021
Published: 14 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Laboratory of Growth Regulators, Institute of Experimental Botany ASCR and Palacký University,
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Abstract: Dihydrofuranocoumarin, chalepin (1) and furanocoumarin, chalepensin (2) are 3-prenylated
bioactive coumarins, first isolated from the well-known medicinal plant Ruta chalepensis L. (Fam:
Rutaceae) but also distributed in various species of the genera Boenminghausenia, Clausena and Ruta.
The distribution of these compounds appears to be restricted to the plants of the family Rutaceae. To
date, there have been a considerable number of bioactivity studies performed on coumarins 1 and
2, which include their anticancer, antidiabetic, antifertility, antimicrobial, antiplatelet aggregation,
antiprotozoal, antiviral and calcium antagonistic properties. This review article presents a critical
appraisal of publications on bioactivity of these 3-prenylated coumarins in the light of their feasibility
as novel therapeutic agents and investigate their natural distribution in the plant kingdom, as well as
a plausible biosynthetic route.
Keywords: Ruta chalepensis; Rutaceae; chalepin; chalepensin; bioactivity; biosynthesis
1. Introduction
Chalepin (1; mol formula: C19H22O4; mol weight 314) and chalepensin (2; mol formula:
C16H14O3; mol weight 254) (Figure 1) are, respectively, a dihydrofuranocoumarin and a
furanocoumarin, with a prenylation at C-3 of the coumarin core structure. These coumarins,
as the names imply, were first isolated from Ruta chalepensis L. (Fam: Rutaceae), but are also
found in other Ruta species, e.g., R. angustifolia and a few other plants of the genus Clausena
(Fam: Rutaceae), e.g., Clausena anisata (Willd.) Hook. F. ex Benth. [1–4]. While chalepin
(1), also known as heliettin, is optically active, chalepensin (2), also known as xylotenin,
does not possess any optical activity. Although these coumarins are rather rare in the sense
that there are not many 3-prenylated naturally occurring furanocoumarins reported to
date, there are quite a good number of bioactivity studies carried out on these compounds.
The present review critically appraises publications on bioactivity of these 3-prenylated
furanocoumarins in the light of their feasibility as novel therapeutic agents and covers their
natural distribution in the plant kingdom, as well as a plausible biosynthetic route.








Figure 1. Structures of chalepin (1) and chalepensin (2). 
2. Distribution 
First isolated from Ruta chalepensis more than half a century ago, chalepin (1) and 
chalepensin (2) have been further reported mainly from various species of the genera 
Clausena and Ruta of the family Rutaceae [4,5]. It appears that these compounds exclu-
sively occur in the family Rutaceae [1–20], and predominantly within these two genera. 
However, Boenminghausenia albiflora var. japonica (Hook.) Rchb. Ex Meisn and B. sessilicarpa 
H. Lev. also produce chalepensin (2) [6,20] and this genus is phylogenetically close to the 
genus Ruta [21]. Chalepensin (2) was further found in the leaves of Esenbeckia alata (Karst 
and Triana) Tr. and Pl. [9], while E. grandiflora Mart. was reported to produce chalepin (1) 
[10]. Interestingly, the genus Esenbeckia Kunth. is a part of a small group of phylogenet-
ically distant Rutaceae including the genera Clausena and Ruta, where 3-prenylated cou-
marins like 1 and 2 are generally produced [9]. Thus, co-occurrence of these 3-prenylated 
furanocoumarins in these genera might have some chemotaxonomic implications, at least 
at the family level, within the family Rutaceae. The distribution of these two coumarins (1 
and 2) is summarized in Table 1. Within the source plants these compounds are well dis-
tributed almost in all parts, leaves, stem, flowers and fruits. Although not chalepensin (2) 
itself, a series of 5-O-prenylated chalepensin derivatives were reported from Dorstenia foet-
ida Schweinf., a medicinal plant from the family Moraceae, distributed in various coun-
tries in the Middle-East Asia [22]. 
Table 1. Distribution of chalepin (1) and chalepensin (2) in the plant kingdom. 
Plant Names Family Chalepin (1) Chalepensin (2) References 
Boenminghausenia albiflora var. japonica (Hook.) 
Rchb. Ex Meisn. 
Rutaceae − + [6] 
Boenminghausenia sessilicarpa H. Lev. Rutaceae − + [20] 
Clausena anisata (Willd.) Hook. F. ex Benth. Rutaceae + − [4,7] 
Clausena emarginata C. C. Huang Rutaceae + − [4,7] 
Clausena indica (Dalz.) Oliver Rutaceae + + [1] 
Clausena lansium (Lour.) Skeels Rutaceae + + [8] 
Esenbeckia alata (Karst & Triana) Tr. & Pl.  Rutaceae − + [9] 
Esenbeckia grandiflora Mart. Rutaceae + − [10] 
Ruta angustifolia L. Pers Rutaceae + − [3,11,12] 
Ruta chalepensis L. Rutaceae + + [5,13–15] 
Ruta graveolens L. Rutaceae + + [16,17] 
Ruta montana L. Rutaceae − + [18] 
Stauranthus perforatus Liebm. Rutaceae + + [19] 
+ = Found; − = Not found. 
3. Biosynthesis 
Like all other coumarins, the biosynthesis of chalepin (1) and chalepensin (2) begins 
from the simple coumarin umbelliferone, which is formed from the amino acid L-phenyl-
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2. Distribution
First isolated from Ruta chalepensis more than half a century ago, chalepin (1) and
chalepensin (2) have been further reported mainly from various species of the genera
Clausena and Ruta of the family Rutaceae [4,5]. It appears that these compounds exclusively
occur in the family Rutaceae [1–20], and predominantly within these two genera. However,
Boenminghausenia albiflora var. japonica (Hook.) Rchb. Ex Meisn and B. sessilicarpa H. Lev. also
produce chalepensin (2) [6,20] and this genus is phylogenetically close to the genus Ruta [21].
Chalepensin (2) was further found in the leaves of Esenbeckia alata (Karst and Triana) Tr. and
Pl. [9], while E. grandiflora Mart. was reported to produce chalepin (1) [10]. Interestingly,
the genus Esenbeckia Kunth. is a part of a small group of phylogenetically distant Rutaceae
including the genera Clausena and Ruta, where 3-prenylated coumarins like 1 and 2 are
generally produced [9]. Thus, co-occurrence of these 3-prenylated furanocoumarins in these
genera might have some chemotaxonomic implications, at least at the family level, within
the family Rutaceae. The distribution of these two coumarins (1 and 2) is summarized
in Table 1. Within the source plants these compounds are well distributed almost in all
parts, leaves, stem, flowers and fruits. Although not chalepensin (2) itself, a series of
5-O-prenylated chalepensin derivatives were reported from Dorstenia foetida Schweinf., a
medicinal plant from the family Moraceae, distributed in various countries in the Middle-
East Asia [22].
Table 1. Distribution of chalepin (1) and chalepensin (2) in the plant kingdom.
Plant Names Family Chalepin (1) Chalepensin (2) References
Boenminghausenia albiflora var. japonica
(Hook.) Rchb. Ex Meisn. Rutaceae − + [6]
Boenminghausenia sessilicarpa H. Lev. Rutaceae − + [20]
Clausena anisata (Willd.) Hook. F. ex Benth. Rutaceae + − [4,7]
Clausena emarginata C. C. Huang Rutaceae + − [4,7]
Clausena indica (Dalz.) Oliver Rutaceae + + [1]
Clausena lansium (Lour.) Skeels Rutaceae + + [8]
Esenbeckia alata (Karst & Triana) Tr. & Pl. Rutaceae − + [9]
Esenbeckia grandiflora Mart. Rutaceae + − [10]
Ruta angustifolia L. Pers Rutaceae + − [3,11,12]
Ruta chalepensis L. Rutaceae + + [5,13–15]
Ruta graveolens L. Rutaceae + + [16,17]
Ruta montana L. Rutaceae − + [18]
Stauranthus perforatus Liebm. Rutaceae + + [19]
+ = Found; − = Not found.
3. Biosynthesis
Like all other coumarins, the biosynthesis of chalepin (1) and chalepensin (2) be-
gins from the simple coumarin umbelliferone, which is formed from the amino acid
L-phenylalanine through the formation of trans-cinnamic acid, p-coumaric acid, 2-hydroxy-
p-coumaric acid, 2-glucosyloxy-p-coumaric acid and 2-glucosyloxy-p-cis-coumaric acid
aided by different enzymes, e.g., cinnamate 4-hydroxylase and 4-coumarate-CoA ligase,
4-coumaroyl 2′-hydroxylase (Figure 2) [23,24]. Sharma et al. [25] studied the biosynthesis
of chalepin (1) in Ruta graveolens. They suggested that 3-(1,1-dimethylallyl)-umbelliferone
could be the key intermediate for the biosynthesis of chalepin (1), and the dihydrofuran
moiety in chalepin (1) is formed via prenylation, aided by dimethylallyldiphosphate, at
C-6 of the core coumarin skeleton followed by oxidative cyclization with neighboring
hydroxyl function at C-7. Generally, prenyltransferases (6-prenyltransferase was identified
in R. graveolens as a plastidic enzyme) are considered the enzymes involved in the biosyn-
thesis of furano-/dihydrofuranocoumarins through umbelliferone prenylation. Further
oxidation of chalepin (1) could lead to the formation of the furanocoumarin chalepensin
(2) in a similar fashion as observed in the conversion of marmesin to psoralen [26]. In fact,
biosynthesis of chalepin (1) resembles that of 3-prenylated furanocoumarin, rutamarin
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(acetyl-chalepin) [26]. At this moment, it is not clear from the literature if the prenylation at
C-3 takes precedence over that on C-6. In fact, the published information on the biosyn-
thesis of these coumarins 1 and 2 is rather extremely limited, and much work, especially
using radioisotopes is much needed to explore other possible routes to the biosynthesis of
these compounds.
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4. Bioactivity
The general, Clausena and Ruta, the main sources of chalepin (2) and chalepensin
(2), are well known for their uses in traditional medicines, and different studies have
established their bioactivities [27,28]. Chalepin (1) and chalepensin (2) have emerged as
two major bioactive components in many of those plants through bioassay-guided isola-
tion protocols, and their bioactivities include antimicrobial, anti-inflammatory, anticancer,
antiviral and many more. In this section, using several subsections, a critical appraisal
is presented on bioactivities of these two compounds (1 and 2) reported in the literature
to date (Table 2) [29–51]. Most of the reported bioactivity studies on these compounds
involved predominantly in vitro assays and only a handful of in vivo and in silico stud-
ies. However, there is no report on any systematic preclinical or clinical trial with these
compou ds involving human volunteers available in the literature to date.
Table 2. Reported bioactivities of chalepin (1) and chalepensin (2).
Bioactivity Chalepin (1) Chalepensin (2) References
Antidiabetic + NR [8]
Antifertility + + [13,29]
Antimicrobial + + [4,30–32]
Antiplatelet aggregation NR + [17]
Antiprotozoal + + [5,33–38]
Antiviral + NR [39–41]
Calcium antagonist NR + [6]
Cytotoxicity (potential anticancer and antitumor) + + [3,7,11,12,42]
Spasmolytic + NR [43]
Effect on drug metabolizing enzymes NR + [44–49]
Mutagenicity and other toxicities + NR [50,51]
NR = No report available; + = Active.
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4.1. Antidiabetic Activity
Among the bioactive compounds isolated from the stem bark of Clausena lansium (Lour.)
Skeels, chalepin (1) exhibited antidiabetic properties, exerted through dose-dependent stim-
ulated (glucose-mediated) insulin release in vitro from INS-1 cells (rat insulinoma cell
line) [8]. Chalepin (1) showed 138% insulin secretory response in vitro at the concentration
of 0.1 mg/mL. INS-1 cells are widely used as rat islet β-cell models for screening for antidi-
abetic properties of plant extracts or purified compounds. They express muscarinic M1 and
M3 receptors, which are activated by carbachol to promote insulin release. Chalepensin
(2) does not appear to have gone through any antidiabetic screening yet. It is known that
insulin secretion involves a sequence of events in β-cells that lead to fusion of secretory
granules with the plasma membrane; it is secreted primarily in response to glucose, while
other nutrients such as free fatty acids and amino acids can augment glucose-induced
insulin secretion.
4.2. Antifertility Activity
During the assessment of the extracts of R. chalepensis var latifolia for antifertility
activity in rodents, chalepin (1) and chalepensin (2) were discovered as the major active
antifertility principles in the extracts [13]. Despite these compounds showing antifertility
activity, most of the tested animals developed cystic and atretic follicles in their ovaries
and glomerulocapsular adhesion and segmental fusion in the kidneys. However, no brain
toxicity was observed with these compounds. Kong et al. [29] assessed the antifertility
activity of the chloroform extracts of the roots, stem and leaves of R. graveolens L. in
rats and fractionation of the extracts afforded coumarin 2 as the active component with
moderate toxicity. Time-dosing experiments showed that this coumarin (2) could act at
the early stages of pregnancy. The observed antifertility activity of 1 and 2 [13,29] could
provide some scientific evidence in support of the traditional uses of R. chalepensis as
an abortifacient.
4.3. Antimicrobial Property
Antimicrobial assay-guided analysis of a root extract of Clausena anisata (Willd.) Hook.
f. Benth., a well-known medicinal plant used traditionally for the treatment of parasitic
infections, influenza, abdominal pain and constipation, afforded chalepin (1) as an antibac-
terial agent, particularly effective against Bacillus subtilis with a zone of inhibition of 16 mm
as opposed to 15 mm of the positive control cifrofloxacin [4]. This coumarin was also found
active against two other pathogenic bacterial strains, Staphylococcus aureus and Pseudomonas
aeruginosa. Chalepensin (2), on the other hand, was reported to possess antifungal property
and was found to inhibit the growth of the fungal strains, Candida albicans and Cryptococcus
neoformans [30]. However, interestingly, none of these coumarins showed any antimicrobial
activity at tested concentrations (50-100 µg/mL) against a range of microorganisms, e.g.,
Bacillus subtilis, Mycobacterium smegmatis, Staphylococcus aureus and Candida albicans, using a
modified microtitre-plate assay as reported by El Sayed et al. [52]. Chalepensin (2), isolated
from R. chalepensis, was assessed for antibacterial activity against Streptococcus mutans
using the method of colony forming units counts in solid medium culture and reduction
of tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
in liquid medium [31] and was shown to significantly inhibit the growth of this bacterial
strain with an MIC (minimum inhibitory concentration) of 7.8 µg/mL.
In the most recent study [32] on anti-MRSA (methicillin-resistant Staphylococcus aureus)
activity of several compounds, mainly coumarins and flavonoids, isolated from R. chalepen-
sis grown in Iraq, both chalepin (2) and chalepensin (3) showed significant antimicrobial
activities against the MRSA strains, ATCC 25923, SA-1199B, XU212, MRSA-274819 and
EMRSA-15 with MIC values ranging between 32 and 128 µg/mL. In that study, two other
furanocoumarins, bergapten and isopimpineline, which do not have a 3-prenylation as
in 1 and 2, were found inactive at tested concentrations. Based on this finding, it was
suggested that the prenylation at C-3 of the coumarin nucleus might be a key determi-
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nant of anti-MRSA activity. Chalepensin (2) was found to be more active than chalepin
(1) and was subjected to in silico studies to gain an insight into the extent at which this
compound (2) is able to bind to MRSA proteins and also their drug−like physicochemical
characters. In silico studies on compound 2 showed that this compound could have high
GI absorption and no violation of the Lipinski rules. It was also shown that chalepensin (2)
could bind with certain MRSA protein targets, predominantly through hydrogen bonding
as well as van de Waals forces. It was suggested that this coumarin could be utilized as a
structural template for generating structural analogs and developing potential anti-MRSA
therapeutic agents.
4.4. Antiprotozoal Activity
One of the major traditional medicinal uses of R. chalepensis and other Ruta species is
their efficacy as antiparasitic agents [28], particularly as an anthelmintic medication. This
traditional medicinal use of R. chalepensis has prompted antiparasitic activity screening
of its extracts and isolated major compounds, including chalepin (1) and chalepensin (2).
Antiprotozoal activity of chalepin (1) and chalepensin (2), obtained from R. chalepensis
following a bioassay-guided protocol, against Entamoeba histolytica, which is a causative
organism of ameoebiasis, was reported as a meeting presentation, but no further full
scientific report was published [33]. Both coumarins showed >90% growth inhibition
against E. histolytica, an anaerobic parasitic amoebozoan, at a concentration of 150 µg/mL
with IC50 values of 28.67 and 38.71 µg/mL, respectively, for compounds 1 and 2. However,
in a previous study [5], conducted by the same group, evaluated antiprotozoal activity
of plants used in northwest Mexican traditional medicine, particularly Lippia graveolens
Kunth. and R. chalepensis, against E. histolytica, and chalepensin (2) was found to be the
main antiprotozoal component in R. chalepensis. Earlier, Kundu and Roy [34] carried out
in silico studies involving chalepin (1) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) of the pathogenic protozoa E. histolytica. It can be noted that GAPDH is a
major glycolytic enzyme (~37 kDA), which catalyzes the sixth step of glycolysis, and an
attractive drug target like E. histolytica lacks a functional citric acid cycle and exclusively
depends on glycolysis for its energy needs. Chalepin (1) was predicted as a GAPDH
inhibitor and structural modifications offering additional polar interactions were suggested
to improve potency.
Trypanosoma cruzi, a species of parasitic euglenoids, characteristically can bore tissue
in another organism and feed on blood and lymph, causing diseases like Chagas disease
(also known as American trypanosomiasis) in humans, that affects more than 7 million
people worldwide, with Latin American countries being most affected. In recent years, a
renewed interest has been observed in the search for antitrypanosomal natural products,
especially from higher plants. In many in vitro as well as in silico studies, glycosomal
glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) from T. cruzi has been used as a
target molecule for screening compounds for potential antitrypanosomal activity [35]. In
an in silico study with various natural products, chalepin (1) emerged as a hit molecule for
antitrypanosomal drug discovery [36], and subsequently, a series of 3-piperonylcoumarins
were synthesized and tested for their inhibitory activity against gGAPDH. Chalepin (1)
was shown in silico to possess the highest binding affinity to gGAPDH (IC50 = 55.5 µM)
among the natural coumarins screened and the best inhibitor of gGAPDH [36,37]. Earlier,
during an in vitro screening of natural coumarins for trypanocidal or antitrypanosomal
activity, chalepin (1) was found to be the most active coumarin with an IC50 value of
64 µM [38]. However, to the best of our knowledge, there is no report available to date on
antitrypanosomal property of chalepensin (2).
4.5. Antiviral Activity
Chalepin (1), isolated from R. graveolens, along with its 28 synthetic analogs were
tested for their inhibitory activity on the Epstein–Barr virus (EBV, also known as human
herpes virus 4) lytic replication activity [41]. It was noted that most of the synthesized
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analogs were more active than their parent or precursor, (-)-chalepin (1). EVP is a human
gamma-herpes virus that infects more than 90% of the human population globally, and
preferentially infects B lymphocytes and epithelial cells causing various diseases like
Hodgkin’s disease, Burkitt’s lymphoma, nasopharyngeal carcinoma and gastric carcinoma
in humans. Thus, inhibition of EBV lytic replication is considered as one of the pragmatic
strategies for the treatment of some these diseases.
Chalepin (1), isolated from the leaves of R. angustifolia, displayed significant inhibitory
activity (IC50 = 1.7 µg/mL) against hepatitis C virus replication and was found to be more
potent than the positive control ribavirin (IC50 = 2.8 µg/mL), a well-known antiviral drug
used for the treatment of hepatitis C and other viral diseases [39]. In continuation of their
study, they have recently reported enhancement of antihepatitis C virus activity of chalepin
(1) in combination with conventional antiviral drugs including cyclosporine A, daclatasvir,
ribavirin, simeprevir and telaprevir [40]. It was found that chalepin (1) could enhance
antihepatitis C activities of these conventional drugs with a synergistic combination index
of <1. It could be considered as an excellent finding as the need for new and effective drugs
for treating hepatitis C is of paramount importance. It can be mentioned that hepatitis C
virus infects around 71 million people globally, causes severe liver disease, e.g., liver cancer
and deaths; the WHO (World Health Organization) estimated that in 2016, about 400,000
people died from hepatitis C, mainly from liver cirrhosis and liver cancer [53,54].
Like many other antiviral coumarins including some 3-substitued ones, it can be
assumed that chalepin (1) might offer antiviral activity through inhibition of various
proteins that are involved in the transcription/translation processes essential for viral life
cycle at different stages, and via modulation of host cell signaling, NF-kB (nuclear factor
κB), and inflammatory redox-sensitive pathways and thus blocking viral replication [54].
However, clearly, further research is necessary to understand and establish definite mode
of antiviral action mechanism of chalepin (1). However, there is no data available on any
antiviral property of chalepensin (2) to date.
4.6. Cytotoxicity (Potential Anticancer and Antitumor Activity)
Cancer is one of the major causes of human mortality and morbidity. Currently
available cancer treatment options or modalities are rather limited, and often suffer from
severe side effects. Therefore, the search for new, effective, safe and affordable anticancer
drugs is a part of many major modern drug discovery initiatives worldwide. Natural
products have long been considered one of the major contributors in the continuing search
for new anticancer molecules for safer and more effective anticancer drug development, and
evidently, have already provided several successful anticancer drugs, e.g., taxol, vincristine
and vinblastine [55]. The most common starting point in the search for anticancer molecules
is the screening compounds for cytotoxicity against various human cancer cell lines because
cytotoxicity is regarded as one of the major characteristics of anticancer agents. In order
to assess anticancer potential of chalepin (1) and chalepensin (2), cytotoxicity of these
compounds has been assessed against different human cancer cell lines in vitro, and some
mechanistic studies on how they kill the cancer cells have also been published, showing
anticancer and antitumor potential of these compounds (Table 2).
Chalepin (1), isolated from Clausena emarginata C. C. Huang, has been found to possess
significant cytotoxicity against five human cancer cell lines including human leukemia (HL-
60), hepatocarcinoma (SMMC-7721), lung carcinoma (A-549), breast cancer (MCF-7) and
colon adenocarcinoma (SW-480) with IC50 values comparable to that of the positive control,
doxorubicin [7]. Chalepin (1), isolated from Ruta angustifolia Pers., was demonstrated to
induce apoptosis through phosphatidylserine externalizations and DNA fragmentation in
breast cancer cell line, MCF-7 [12,42]; this compound was considerably cytotoxic to MCF-7
cells, moderately cytotoxic to the epithelial human breast cancer cells (MDA-MB231), but
not cytotoxic to normal cells, MRC-5 (Medical Research Council cell strain 5) in the SRB
(sulforhodamine B) assay [56]. MRC-5 is a diploid cell culture line comprising fibroblasts,
first developed from the lung tissue of a 14-week-old aborted Caucasian male fetus. It can be
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mentioned here that apoptosis is a process by which cell commit suicide and is eliminated
from the system; induction of apoptosis, a cell toxicity pathway, is considered as one of
the early-stage mechanism for compounds to exert anticancer activity. This differential
cytotoxicity against cancer cells and noncancerous cells might make this compound an
ideal candidate, or at least a structural template, for anticancer drug development.
Earlier, in order to understand how chalepin (1) could exert its anticancer potential,
a study conducted by Richardson et al. [11], revealed that this compound could dose-
dependently exhibit cell cycle arrest at S phase, suppress nuclear factor kappa B (NFκB)
pathway, signal transducer and activation of transcription 3 phosphorylation and extrinsic
apoptotic pathway in human non-small cell lung cancer cell line A-549. Cell cycle analysis
using the flow cytometry confirmed that chalepin (1) could inhibit cell cycle at S phase
(synthesis phase), which is the phase of the cell cycle, where DNA is replicated and occurs
between the G1 and G2 phases. Since accurate duplication of the genome is essential for
successful cell division to take place, the processes involved in the S phase are tightly
regulated and widely conserved. A significant accumulation of cells in the S phase was
observed after chalepin (1) treatment (45 µg/mL) for 48 (accumulation 27.7%) and 72 h
(accumulation 25.4%), whereas the accumulation was only about 4% for the untreated
cells [11]. It is well known that there is a remarkable link between cell cycle and cancer, as
cell cycle appears to be the machinery that controls cell proliferation, and uncontrolled cell
proliferation happens in cancer. The suppression of the NF-κB pathway by chalepin (1) was
shown to be through modulation of the p65 subunit of NF-κB, where the phosphorylation
of p65 and the translocation of the p65 subunit to nucleus were inhibited [11]. It can be
noted that the NF-κB pathway is generally induced by carcinogens and inflammatory
agents. Thus, suppression of NF-κB pathway by chalepin (1) could suggest its potential as
an anticancer agent.
Caspase 8 is implicated to the activation of the intrinsic apoptotic pathway, and en-
hancement of caspase 8 activity can be exploited to identify compounds with plausible
anticancer activity. In chalepin (1) treated cells, a significantly increased level of caspase 8 ac-
tivity was noticed, when compared to the control; after 48 and 72 h of incubations, chalepin
(1) (45 µg/mL) enhanced caspase 8 activity, respectively, by 5-fold and 8.6-fold [11].
This group of researchers also demonstrated that chalepin (1) and chalepensin (2)
could induce mitochondrial mediated apoptosis in lung carcinoma cells (A-549), with
chalepin (1) being more cytotoxic than chalepensin (2) [3]; chalepin (1) exhibited selective
cytotoxicity against A-549 cells with an IC50 value of 8.69 µg/mL (27.64 µM). Chalepin (1)
was mildly toxic to the normal cell line with an IC50 value of 23.4 µg/mL. Chalepensin
(2) exhibited considerable cytotoxic property against A-549 cell line with IC50 value of
18.5 µg/mL, while the cytotoxicity (IC50 = 23.4 µg/mL) of this coumarin against noncancer-
ous MRC-5 human lung fibroblast cell line was of moderate level as was with chalepin
(1). Chalepin (1) showed morphological changes, typical for apoptosis, e.g., plasma mem-
brane blebbing, cell vacuolization, echinoid spiking, chromatin condensation, formation
of apoptotic bodies, cell shrinkage and nuclear fragmentation. Both coumarins (1 and 2)
were found to downregulate inhibitors of apoptosis such as Bcl-2, survivin, Bcl-xl and
cFLIP. They also triggered release of cytochrome c and activated caspases 9 and 3 to induce
apoptosis. Chalepensin (2) was shown to possess cytotoxicity against colon (H-T29), lung
(A-549), breast (MCF-7), kidney (A-498), and pancreatic (PACA-2) cancer cell lines [3].
Wu et al. [17] screened 19 compounds isolated from Ruta chalepensis, including
chalepensin (2), for their potential cytotoxicity against KB (keratin forming tumor), Hela,
DLD (colorectal adenocarcinoma) and Hepa tumor cell lines, but chalepensin (2) was found
to be inactive against any of these cell lines at tested concentrations. From the available
literature data, it is obvious that chalepin (1) is more cytotoxic than chalepensin (2). How-
ever, considerably more work has been carried out with chalepin (1) than with chalepensin
(2) to date, and further comparative work may be necessary to gain a better insight into
their anticancer potential.
Molecules 2021, 26, 1609 8 of 12
4.7. Miscellaneous Activities
Spasmolytic activities of chalepin (1) and a few other coumarins, isolated from Boen-
ninghausenia albiflora (Hook.) Rchb. Ex Meisn., were reported by Rizvi et al. [43]. Ef-
fects of aqueous extracts of R. graveolens and its ingredients, chalepensin (2) being one
of them, on major drug metabolizing enzymes, cytochrome P450, uridine diphosphate
(UDP)-glucuronosyltransferase and reduced nicotinamide adenine dinucleotide (phos-
phate) (NAD(P)H)-quinone oxidoreductase, were evaluated in mice [15]. The repeated
administration of R. graveolens extract, rich in rutin and chalepensin (2), could induce
hepatic CYP1a and CYP2b activities in a dose-dependent fashion. It was observed that
male mice were more responsive than female mice to the extract-medicated induction
of UGT (uridine glucuronosyltransferase). Earlier, the same group of researchers [48]
showed mechanism-based inhibition of CYP1a1 and CYP3A4 by chalepensin (2), while
this compound was also found to inhibit human CYP1a2, CYP2a13, CYP2c9, CYP2d6
and CYP2e1.
In order to study the in vivo effect of chalepensin (2), Lo et al. [44] assessed its effect
on multiple hepatic P450 enzymes in C57BL/6JNarl mice, and observed that this coumarin,
after oral administration (10 mg/kg) in mice for 7 days, could decrease hepatic coumarin
7-hydroxylation by CYP2a, and increase 7-pentoxyresorufin O-dealkylation by CYP2b,
without affecting the activities of other CYP enzymes. It was further observed that the
suicidal inhibition of CYP2a5 and the constitutive androstane receptor (CAR) mediated
CYP2b9/10 induction simultaneously happened in chalepensin (2)-treated mice. Previously,
Ueng et al. [46,47] and Lo et al. [45] carried out related extensive studies on mechanism-
based inhibition of CYP enzymes by chalepensin (2) in various in vitro and in vivo models.
However, there is no report on such activities of chalepin (1) available in the published
literature to date.
In a study conducted by Wu et al. [17], chalepensin (2) at 100 µg/mL concentration
displayed significant antiplatelet aggregation activity, induced by arachidonic acid and
collagen. This coumarin, isolated from Boenninghausenia albiflora var. japonica, was also
reported to possess calcium antagonistic property [6].
5. Mutagenicity and Other Toxicities
The mutagenicity of chalepin (1) was assessed at the HGPRT locus (AzGr) in Chinese
hamster V79 cells [50], and this compound was found to be mutagenic. Chalepin (1),
isolated from Clausena aniseta, a well-known medicinal plant from West Africa, showed
anticoagulant (blood-thinning) activity when administered to rats in a single dose [51],
and it could depress aniline hydroxylase activity. Ethylmorphine demethylase, hepatic
DNA, reduced glutathione and glucose-6-phosphatase were unaffected by chalepin (1)
treatment at a dose of 50 mg/kg for 3 days prior to sacrifice. This coumarin also resulted in
α-1-globulin increase and a decrease in β-globulin content of the serum. Intraperitoneal
treatment with chalepin (100 mg/kg) for 2 days caused death of 4 rats out of 100 within 48 h
of treatment. Livers of dead rats showed generalized necrosis of hepatocytes. Chalepin
(1) induced alterations in the serum protein pattern within this period. Liver lesions
were observed in chalepin treated animals and were characterized by mild necrosis of
hepatocytes. However, no report on mutagenicity of chalepensin (2) is available to date.
6. Drugability’ of Chalepin (1) and Chalepensin (2)
“Drugability” can simply be defined as the ability of a compound to be used as a phar-
maceutical drug. In order for a molecule to be developed as a drug, it must have certain
physicochemical characteristics, which can be measured or predicted by various experimen-
tal or mathematical models. The Lipinski rule of five, formulated in 1997 by Christopher A.
Lipniski, can be used, albeit not conclusively, to predict whether a compound could be an
ideal candidate as a drug molecule, i.e., whether a compound possesses “druglikeness” or
not [57]. This rule states that an orally active drug does not have more than one violation of
the following criteria: a molecular mass less than 500 Daltons, no more than five hydrogen
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donors, no more than 10 hydrogen bonds and an octanol-water partition coefficient (log P)
that does not exceed five. Sometimes an additional criterion, “molar refractivity should be
between 40–130” is also added to the above rule. If we consider these criteria in relation to
chalepin (1) and chalepensin (2), both compounds tend to follow Lipinski rule of five, and
there is no violation of this rule whatsoever (Table 3), which suggests that these compounds
possess “druglikeness” or “drugability” and have the potential for further development as
commercial drugs. However, it must be noted that this rule of five was originally presented
to aid the development of orally bioavailable drugs and was not intended for guiding the
medicinal chemistry in the development of all small-molecule drugs. Moreover, there is
hardly any reliable experimental bioavailability data available on these coumarins (1 and 2)
to make any connections between bioavailability and the predicted values for the criteria
shown in Table 3.
Table 3. “Druglikeness” of chalepin (1) and chalepensin (2) *.
Criteria Chalepin (1) Chalepensin (2)
Molar mass 314 254
Hydrogen bond donor 1 0
Hydrogen bond acceptors 4 3
Log P 3.72 4.32
Molar refractivity 86.6 cm3 72.5 cm3
Lipinski rule of 5 violation 0 0
* Data obtained from ChemSpider (www.chemspider.com, (accessed on 24 February 2021)) and
DrugBank (https://go.drugbank.com/drugs/DB02205, (accessed on 24 February 2021)).
7. Conclusions
The present work generated the first comprehensive and critical review of published
literature on chalepin (1) and chalepensin (2), revealing various bioactivities of these com-
pounds and their potential as new therapeutic agents. Among the activities, it appeared
that antiprotozoal, antiviral and particularly anticancer activities bear promises for these
compounds for further consideration for development as therapeutic agents, when con-
sidered in the light of nonviolation of the Lipinski rule of five and low level of toxicities.
However, there is no report on any systematic preclinical or clinical trial with these com-
pounds involving human volunteers available in the literature to date. Therefore, further
studies, including controlled preclinical and clinical trials, are still needed before we can
comment on the true therapeutic potential of these compounds.
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